Appointments

Request an Appointment

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

View Cancer Clinical Trials

CALGB 30901   |   12-645
Randomized Phase II Study of Maintenance Pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first-line chemotherapy

Disease(s)
Mesothelioma
Hospital(s)
Beachwood
Fairview
Hillcrest
Independence
Main Campus
N/A
North Coast Cancer
Strongsville
Wooster
Phase(s)
Phase 2
Stage(s)
N/A
Type(s)
Therapeutic
Drug(s)
Pemetrexed

Contact Information
Cancer Answer Line

866.223.8100

8:00 am - 4:30 pm, Monday - Friday


Description

Primary Objective

  • To determine if maintenance therapy with pemetrexed improves progression-free survival in patients with malignant pleural mesothelioma who have at least stable disease after completion of first-line therapy with pemetrexed plus cisplatin or carboplatin.

Secondary Objective(s)

  • To determine if maintenance therapy with pemetrexed improves overall survival.
  • To evaluate frequency of responses to maintenance therapy with pemetrexed.
  • To assess toxicity of maintenance therapy with pemetrexed.

Inclusion Criteria
  1. Histologic Documentation: Histologically documented malignant pleural mesothelioma, epithelial, sarcomatoid or mixed type, not amenable to surgical resection.
  2. Prior treatment
    • Currently receiving first-line treatment with pemetrexed + platinum. Patients are to be registered to CALGB 30901 no later than the last day of cycle 4 of first line therapy.
    • Prior intracavity cytotoxic or sclerosing therapy (including bleomycin) are acceptable. Prior intrapleural cytotoxic chemotherapy will not be considered systemic chemotherapy.
    • Prior surgical treatment is allowed.
    • Prior radiation therapy is allowed.
  3. Age ≥ 18 years
  4. Non-pregnant and non-nursing since the effects of pemetrexed on the fetus/infant are unknown. In addition, women of child bearing potential and men must agree to use an appropriate method of birth control throughout their participation in this study. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives (Norplant), or double barrier methods (diaphragm plus condom).
  5. Randomization Eligibility Criteria
    • Patients with complete response, partial response, or stable disease following 4, 5, or 6 cycles of first-line chemotherapy with pemetrexed AND either cisplatin or carboplatin. A maximum of 6 cycles of chemotherapy may have been given.
    • ECOG performance status of 0-1
    • Required Randomization Initial Laboratory Data:
      • Granulocytes ≥ 1,500/ ul
      • Platelet count ≥ 100,000/ ul
      • Total Bilirubin ≤ 1.5 x ULN
      • AST (SGOT) ≤ 2 x ULN
      • Calculated Creatinine Clearance * ≥ 45 ml/min. The calculated creatinine clearance will be estimated by the Cockcroft-Gault formula as follows: (140-age) x wt. in kg./72 x serum creatinine x 0.85 for females OR 1.0 for males

Exclusion Criteria
Exclusion Criteria Not Available

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.